{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:21:26Z","timestamp":1789683686605,"version":"4.0.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ijrobp.2025.05.059","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T20:44:29Z","timestamp":1748637869000},"page":"164-170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Prospective Study of Stereotactic Body Radiation Therapy in Oligometastatic Renal Cell Carcinoma"],"prefix":"10.1016","volume":"125","author":[{"given":"Rohan R.","family":"Katipally","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greeshma","family":"Rajeev-Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek A.","family":"Solanki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fauzia","family":"Arif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott E.","family":"Eggener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhinav","family":"Sidana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell Z.","family":"Szmulewitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter M.","family":"Stadler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy F.","family":"Sweis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean P.","family":"Pitroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4701-2469","authenticated-orcid":false,"given":"Stanley L.","family":"Liauw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2025.05.059_bib0001","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1200\/JCO.1994.12.1.206","article-title":"Patterns of failure following surgical resection of renal cell carcinoma: Implications for adjuvant local and systemic therapy","volume":"12","author":"Rabinovitch","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.05.059_bib0002","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.eururo.2023.01.001","article-title":"Outcomes for international metastatic renal cell carcinoma database consortium prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma","volume":"84","author":"Ernst","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2025.05.059_bib0003","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41571-022-00655-9","article-title":"The oligometastatic spectrum in the era of improved detection and modern systemic therapy","volume":"19","author":"Katipally","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.05.059_bib0004","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.radonc.2005.03.022","article-title":"Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma","volume":"77","author":"Wers\u00e4ll","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.05.059_bib0005","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nrurol.2017.87","article-title":"Radiotherapy for renal cell carcinoma: Renaissance of an overlooked approach","volume":"14","author":"Siva","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.ijrobp.2025.05.059_bib0006","article-title":"Primary site stereotactic ablative body radiotherapy in localized, recurrent, and metastatic renal cell carcinoma","volume":"49","author":"Huang","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.05.059_bib0007","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/S1470-2045(21)00528-3","article-title":"Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: A single-arm, single-centre, feasibility, phase 2 trial","volume":"22","author":"Tang","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.05.059_bib0008","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.eururo.2021.12.006","article-title":"Stereotactic radiotherapy and short-course pembrolizumab for oligometastatic renal cell carcinoma-The RAPPORT trial","volume":"81","author":"Siva","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2025.05.059_bib0009","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ijrobp.2015.02.016","article-title":"Gastrointestinal toxicities with combined antiangiogenic and stereotactic body radiation therapy","volume":"92","author":"Pollom","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.05.059_bib0010","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1001\/jamaoncol.2021.0687","article-title":"Evaluation of safety of stereotactic body radiotherapy for the treatment of patients with multiple metastases: Findings from the NRG-BR001 phase 1 trial","volume":"7","author":"Chmura","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2025.05.059_bib0011","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2025.05.059_bib0012","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/jamaoncol.2023.7266","article-title":"Charting the path to systemic therapy de-escalation-Oligometastatic kidney cancer as a paradigm","volume":"10","author":"Tang","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2025.05.059_bib0013","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.3390\/ijms21072532","article-title":"Immunotherapy in renal cell carcinoma: The future is now","volume":"21","author":"Deleuze","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ijrobp.2025.05.059_bib0014","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1038\/bjc.2012.149","article-title":"Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-\u03b1","volume":"106","author":"Patil","year":"2012","journal-title":"Br J Cancer"},{"issue":"15 suppl","key":"10.1016\/j.ijrobp.2025.05.059_bib0015","volume":"39","author":"Cella","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.05.059_bib0016","first-page":"e249","article-title":"Clinical outcomes of patients with oligometastatic renal cell cancer treated with stereotactic body radiation therapy: Results from a prospective registry trial","volume":"120","author":"Lee","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.05.059_bib0017","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.eururo.2021.07.026","article-title":"Stereotactic radiotherapy for oligoprogression in metastatic renal cell cancer patients receiving tyrosine kinase inhibitor therapy: A phase 2 prospective multicenter study","volume":"80","author":"Cheung","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2025.05.059_bib0018","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.euo.2021.12.001","article-title":"Phase II trial of stereotactic ablative radiation for oligoprogressive metastatic kidney cancer","volume":"5","author":"Hannan","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ijrobp.2025.05.059_bib0019","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijrobp.2019.07.023","article-title":"Stereotactic ablative radiation therapy (SAbR) used to defer systemic therapy in oligometastatic renal cell cancer","volume":"105","author":"Zhang","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.05.059_bib0020","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.3390\/cancers16172963","article-title":"Predictive factors for long-term disease control in systemic treatment-na\u00efve oligorecurrent renal cell carcinoma treated with up-front stereotactic ablative radiotherapy (SABR)","volume":"16","author":"Franzese","year":"2024","journal-title":"Cancers"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625005292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625005292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T08:31:54Z","timestamp":1782030714000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301625005292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0360301625005292"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.05.059","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Prospective Study of Stereotactic Body Radiation Therapy in Oligometastatic Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.05.059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}